GRACEcast (lung-cancer-audio)
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. David Spigel, Sarah Cannon Cancer Center, answers audience questions about squamous lung cancer.

Direct download: GRACEcast-182_Lung-Audio_Squamous_Lung_Cancer_Q_and_A_Session.mp3
Category:Lung-Cancer-Audio -- posted at: 12:34am PST

Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.

Direct download: GRACEcast-181_Lung-Audio_Squamous_Lung_Cancer_Immunotherapy.mp3
Category:Lung-Cancer-Audio -- posted at: 3:43pm PST

Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.

Direct download: GRACEcast-180_Lung-Audio_Squamous_Lung_Cancer_Treatment.mp3
Category:Lung-Cancer-Audio -- posted at: 3:07pm PST

Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.

Direct download: GRACEcast-179_Lung-Audio_Squamous_Lung_Cancer_Genomic_Testing.mp3
Category:Lung-Cancer-Audio -- posted at: 10:02am PST

Dr. David Spigel, Sarah Cannon Cancer Center, describes the diagnosis, presentation and workup of squamous lung cancer.


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.

Direct download: GRACEcast-172_Lung-Audio_ASCO_2013_MPDL3280A_NSCLC.mp3
Category:Lung-Cancer-Audio -- posted at: 12:32pm PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, reviews impressive results from the GALAXY-1 trial of the heat shock protein inhibitor ganetespib combined with combined with second line docetaxel in advanced lung adenocarcinoma.

Direct download: GRACEcast-171_Lung-Audio_ASCO_2013_Ganetespib_Second_Line.mp3
Category:Lung-Cancer-Audio -- posted at: 6:56pm PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, discusses results in a trial that demonstrated a significant survival benefit with nintedanib combined with second line docetaxel in advanced lung adenocarcinoma.

Direct download: GRACEcast-170_Lung-Audio_ASCO_2013_Nintedanib_Second_Line.mp3
Category:Lung-Cancer-Audio -- posted at: 4:56pm PST

Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.


Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the results and implications of the MADeIT phase III randomized study of preductive biomarkers ERCC1 and RRM1 in advanced NSCLC.

Direct download: GRACEcast-168_Lung-Audio_ASCO_2013_MADeIT_ERCC1_RRM1.mp3
Category:Lung-Cancer-Audio -- posted at: 11:48am PST